Combination Product Oversight Will Be Partly Affected By Drug GMP Initiative
This article was originally published in The Gray Sheet
Executive Summary
FDA's initiative to enhance pharmaceutical good manufacturing practices will apply to combination products that have biological drug or drug components
You may also be interested in...
CDRH 483s Will Include Language Developed Under GMP Initiative
FDA is seeking to reconcile device Form 483s with new language being added to drug inspection documents under the auspices of CDER's GMP initiative, according to FDA Assistant Commissioner of Regulatory Affairs Steve Niedelman
CDRH 483s Will Include Language Developed Under GMP Initiative
FDA is seeking to reconcile device Form 483s with new language being added to drug inspection documents under the auspices of CDER's GMP initiative, according to FDA Assistant Commissioner of Regulatory Affairs Steve Niedelman
Part 11 Risk-Based Approach To Be Communicated To FDA Field Staff
Device manufacturers should prepare for variability in how inspectors interpret Part 11 requirements as FDA gears-up to communicate more specific guidelines to its field staff in the next several weeks